Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Healthcare topic
No spam. Unsubscribe anytime.
Pennridge hears sharply rising GLP‑1 prescription costs; consultant recommends carrier and stop‑loss renewals
Summary
A benefits consultant told the board GLP‑1 diabetes and anti‑obesity prescriptions have driven prescription costs from hundreds of thousands to over a million dollars in projected claims; staff recommended renewing Independence Blue Cross and negotiating stop‑loss terms including a 50% rate‑cap and a temporary no‑new‑lasers protection.
Benefits consultant Mr. Pi presented a health‑plan update that framed two core pressures: rising medical claims driven by specialty drugs and a rapid increase in GLP‑1 prescriptions for diabetes and weight management.
Mr. Pi said diabetic GLP‑1 costs in the district rose from about $200,000 in 2022–23 to a projected ~$600,000 for 2025–26; anti‑obesity GLP‑1s were projected to reach about $1.3 million. “We’re projecting here for 25/26 that number is going to be about 1.3 million,” he said when describing anti‑obesity drug spend, and noted the data were projected through May with a final month extrapolated.
The consultant emphasized that raw claim figures do not reflect manufacturer rebates negotiated through the pharmacy‑benefit manager (PBM). He said marketplace estimates for rebates on these drugs run roughly 35–45 percent and that, applied at scale, rebates could materially reduce the district’s net exposure on GLP‑1 costs.
On overall plan design and vendor strategy, Mr. Pi summarized an RFP that validated Independence Blue Cross as a competitive medical carrier for 2026–27. He said IBC offered $50,000 in loyalty credits over two years and program commitments—including specialty injectable programs—that staff project could save roughly $160,000 annually.
For stop‑loss, Mr. Pi said the district’s current specific stop‑loss attachment point is $225,000 per member; one high claimant had been lasered at $500,000 in the current year. After market solicitation, the incumbent reinsurer reduced its proposed maximum liability in response to a close Avalon bid; the consultant said contract protections negotiated include a 50% renewal rate cap and a temporary no‑new‑lasers provision for the first year of the renewal.
Mr. Pi also reported that the district’s specialty‑drug program implemented in 2026 saved an estimated $140,000 in the first four months of use, exceeding earlier estimates. He recommended renewing carrier and stop‑loss arrangements with the negotiated protections and continuing to analyze rebate flows and utilization management for high‑cost drugs.
Next steps: staff recommended approving the medical‑carrier renewal strategy and finalizing stop‑loss terms that preserve a 50% rate‑cap and a limited no‑new‑lasers protection while continuing to monitor specialty drug rebates and utilization trends.
